Abstract:Introduction Antipsychotics effectively manage psychotic symptoms but may have side effects. Patients with schizophrenia often lack insight into their condition, leading to nonadherence. Long-acting injectable (LAI) antipsychotics aim to overcome this, reducing relapse risks. Paliperidone LAI, a second-generation antipsychotic, has a lower side effect profile when compared to first-generation counterparts. Blood dyscrasias, like neutropenia and lymphopenia, increase infection susceptibility. This case report describes an instance of leukocytopenia arising during paliperidone LAI treatment, which quickly resolved after the discontinuation of the medication. Objectives This case report describes an instance of leukocytopenia arising during paliperidone LAI treatment, which quickly resolved after the discontinuation of the medication. MethodsResults CASE A 42-year-old female with schizophrenia, nonadherent to previously prescribed medication was admitted to our acute psychiatric department. She experienced positive symptoms (paranoid delusions), as well as disorganized thinking and behavior. Oral risperidone 4 mg two times a day was recommenced and titrated with mild improvement in her psychotic symptoms with the idea of switching to paliperidone LAI and eventually ceasing oral medication. Oral paliperidone was unavailable for prescription due to local restrictions. At admission her routine laboratory tests showed no abnormalities, but 5 days after receiving paliperidone LAI, routine laboratory tests showed a strong decrease in her WBC and absolute neutrophilic and lymphocytic count ( Lkc 2.89x10 9 /L, Neut 1.57x 10 9 /L, Lym 0.88x 10 9 /L ). Antipsychotic-induced blood dyscrasia was suspected and paliperidone depot was discontinued. The patient had rapid improvement in her WBC reaching the reference range in 10 days ( Lkc 4.23 x 10 9 /L, Neut 2.51x10 9 /L, Lym 0.98x 10 9 /L). Sertindole was introduced consdering her history of a good therapeutic response to the drug, with improvement in psychotic symptoms. She is currently stable taking sertindole 16 mg/day, clonazepam 2 mg/day and alprazolam 0.5 mg/day. DISCUSSION The onset of neutropenia and lymphopenia post-paliperidone LAI initiation, resolving in 10 days,, indicate a direct association. Few cases report to date describe paliperidone-induced leukocytopenia, with rapid recovery post-discontinuation. Proposed mechanisms include bone marrow suppression and peripheral WBC destruction. It has been proposed that drug-induced neutropenia is often dose-dependent, which could explain why our patient exhibited tolerability to risperidone but developed cytopenia upon transitioning to depot paliperidone. Conclusions While cases of agranulocytosis have been reported in association with the use of other antipsychotics these antipsychotics do not require the same monitoring as clozapine. Our case emphasizes the need for vigilant blood dyscrasia monitoring during antipsychotic therapy. Disclosure of Interest None Declared

Risperidone-Induced Leukoneutropenia: Evidence from a Positive Rechallenge and Review of the Literature

Efficacy and Safety of Long-Acting Risperidone on Early Onset Schizophrenia in Adolescent Patients

Risperidone-induced changes in DNA methylation from peripheral blood in first-episode schizophrenia parallel neuroimaging and cognitive phenotype

Metabolic Side Effects of Risperidone in Pediatric Patients with Neurological Disorders: A Prospective Cohort Study

High vulnerability to adverse reactions to antipsychotics: A case report

High vulnerability to adverse reactions toantipsychotics: a case report

Risperidone-induced bioenergetic disruption in the isolated human peripheral blood monocytes

Successful Clozapine Rechallenge After Clozapine-Induced Severe Anemia: A Case Report

Blood Dyscrasias Induced by Psychotropic Drugs

Risperidone-induced changes in DNA methylation in peripheral blood from first-episode schizophrenia patients parallel changes in neuroimaging and cognitive phenotypes

Effect of Risperidone on Serum Homocysteine Levels in First-Episode, Drug-Naïve Patients with Schizophrenia.

Risperidone-Induced Urinary Incontinence in Schizoaffective Disorder: A Case Report

Short-term Effects of Risperidone Monotherapy on Spontaneous Brain Activity in First-episode Treatment-naïve Schizophrenia Patients: A Longitudinal Fmri Study

Altered Antioxidant Defenses in Drug-Naive First Episode Patients with Schizophrenia Are Associated with Poor Treatment Response to Risperidone: 12-Week Results from a Prospective Longitudinal Study

Relationship between plasma risperidone concentrations and clinical features in chronic schizophrenic patients in China

Risperidone-Associated Prolactin Elevation And Markers Of Bone Turnover During Acute Treatment

Haematological alterations in the context of olanzapine treatment

Risperidone Exacerbates Glucose Intolerance, Nonalcoholic Fatty Liver Disease, and Renal Impairment in Obese Mice

Into a Deeper Understanding of CYP2D6's Role in Risperidone Monotherapy and the Potential Side Effects in Schizophrenia Spectrum Disorders

Paliperidone LAI-Induced Leukocytopenia: A Case Report

Drug Attitudes and Treatment Adherence in A Clinical Trial Comparing Haloperidol and Olanzapine in First Episode Schizophrenia